This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Actinobac Biomed Receives $202,000 From NIH To Advance Blood Cancer Research

NEW BRUNSWICK, N.J., March 28, 2013 /PRNewswire-USNewswire/ -- Actinobac Biomed Inc, originally funded with an investment from Foundation Venture Capital Group, Inc., has received a $202,000 Small Business Technology Transfer Grant (STTR) from the National Institutes of Health* to study its drug candidate, Leukothera®, as a potential treatment for B-cell lymphomas.

The STTR program seeks to increase participation of small businesses in Federal R&D programs and to increase private sector commercialization of early stage technologies. The unique feature of the STTR program is the opportunity for small business concern applicants to formally collaborate with research institutions. This project is being conducted in collaboration with Dr. Joseph Bertino, chief scientific officer at the Cancer Institute of New Jersey in New Brunswick, NJ.

According to Actinobac founder Dr. Scott Kachlany, the grant will allow them to perform research which will include animal studies to examine the effect of Leukothera® in mouse models for B-cell lymphomas.

"Based upon the fact that preclinical efficacy studies have shown that Leukothera® is highly effective at eliminating leukemia cells in animals under laboratory conditions, we are hopeful that we'll continue to see efficacy for lymphomas," he said.

Leukothera® is a natural biologic agent that specifically targets and depletes disease related white blood cells.  In studies to date, malignant and proinflammatory white blood cells have been determined to be significantly more sensitive to Leukothera® than normal white blood cells. 

Foundation Venture Capital Group invested $500,000 in 2009 when Actinobac was first established to develop pharmaceutical agents for the treatment of hematologic malignancies (leukemias & lymphomas), autoimmune diseases  (rheumatoid arthritis, multiple sclerosis, Crohn's disease, type 1 diabetes, lupus, and psoriasis), and HIV infection.  It recently made an additional $100,000 investment to further studies in the treatment of white blood cell diseases in dogs which can be used to design cancer treatments for companion animals and support the continued development of Actinobac's drug candidate for human health care purposes.

Actinobac has exclusive rights to the therapeutic use of Leukothera® through a license from the University of Medicine and Dentistry of New Jersey.

*Research described in this article is supported by the National Cancer Institute of the National Institutes of  Health under Award Number R41CA173900. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs